Pharmaceutical composition for treating viral hepatitis

A composition and drug technology, applied in the field of compounds and pharmaceutical compositions for the treatment or prevention of viral hepatitis, can solve the problems of no direct effect on HBeAg and HBsAg clearance, huge medical costs due to drug resistance, side effects of drugs, and reduction of HBV DNA, etc., to achieve Excellent clinical safety and pharmacokinetic properties, improved clearance of hepatitis B virus, good synergistic effect

Active Publication Date: 2022-05-20
北京中以海德医学研究有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although these reverse transcriptase inhibitors can effectively reduce the level of HBV DNA and enable patients to control the level of hepatitis B virus, they have no direct effect on the clearance of HBeAg and HBsAg because their target is the process of reverse transcription of RNA into DNA
Therefore, the probability of HBeAg and HBsAg seroconversion in nucleoside analog monotherapy is extremely low, and it cannot really cure hepatitis B. Patients need to take drugs for a long time or even for life
[0007] Although the above-mentioned reverse transcriptase inhibitors can enable patients to control the level of hepatitis B virus, the resulting drug resistance, huge medical expenses, and serious side effects of drugs should not be underestimated.
The point is that there is still no drug that can completely clear the virus and achieve a functional cure for hepatitis B

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating viral hepatitis
  • Pharmaceutical composition for treating viral hepatitis
  • Pharmaceutical composition for treating viral hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0056] Evaluation of the synergistic effect of lansoprazole, celecoxib and rapamycin against HBV in vitro using HepG2-NTCP cells

[0057] 1. Compound

[0058] Celecoxib (code HD042), lansoprazole (code HD017) and rapamycin (HD082) were purchased from Shanghai Taosu Biotechnology Co., Ltd.

[0059] Compound preparation method is as follows:

[0060] Take the preparation of 20mM concentration as an example, the volume of solvent DMSO (μl) = sample mass (mg) × purity ÷ molecular weight ÷ 20 × 10 6

[0061] The control compound was entecavir (ETV, batch number: P1214012; 99.0% purity), which was purchased from Shanghai Titan Technology Co., Ltd. The concentrations of the mother solutions of the above compounds were all 20 mM and stored at -20°C.

[0062] 2. Cells and media

[0063] HepG2-NTCP cells: provided by Shanghai WuXi PharmaTech New Drug Development Co., Ltd.

[0064] Freezing PHH culture medium: mainly DMEM medium (Gibco product number 11960051) containing 10% fetal ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition for treating viral hepatitis, which comprises a proton pump inhibitor, a non-steroidal anti-inflammatory drug and an mTOR inhibitor, application of the pharmaceutical composition for treating or preventing the viral hepatitis, and application of the pharmaceutical composition in preparation of drugs for treating or preventing the viral hepatitis, especially hepatitis B.

Description

technical field [0001] The present application relates to the technical field of antiviral drugs, in particular, to a compound, pharmaceutical composition and application thereof for treating or preventing viral hepatitis. Background technique [0002] Human hepatitis B virus (HBV) infection is an important public health problem worldwide. After acute hepatitis B virus infection, about 8% still develop into chronic hepatitis B infection, and persistent HBV infection will lead to liver cirrhosis and even liver cancer. Hepatitis B transmission is mainly through vertical transmission and horizontal transmission. Vertical transmission refers to mother-to-child transmission; horizontal transmission is mainly through blood. [0003] The treatment of hepatitis B is also a long-term process. The goal of treatment is to suppress or eliminate HBV to the greatest extent, reduce inflammation and necrosis of liver cells and liver fibrosis, delay and prevent disease progression, reduce ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/635A61K9/20A61K9/48A61P1/16A61P31/20A61P31/14A61K31/4439A61K31/436
CPCA61K45/06A61K31/4439A61K31/635A61K31/436A61K9/0053A61K9/20A61K9/48A61P1/16A61P31/20A61P31/14A61K2300/00
Inventor 李瑛颖陈明键仇思念
Owner 北京中以海德医学研究有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap